TSHATaysha Gene Therapies, Inc.
$3.97-22% 1Y
$3.97
$3.5052 weeks$6.98
Is the business good?
How good a business is TSHA?
Taysha Gene Therapies, Inc. spent more than it took in: an operating loss of $153M on $5.5M of revenue, 12 months to Q2 2026.
$153M
Operating loss · on $5.5M of revenue · 12 months to Q2 2026
- Share count, year on year
- +24%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2022 | −6493% |
| FY2023 | −469% |
| FY2024 | −1098% |
| FY2025 | −1131% |
Details›
- Operating margin12 months to Q2 2026
- −2792%
- Net margin12 months to Q2 2026
- −2728%
- Free cash flow margin
- −2417%
- R&D as % of revenue
- 2245%
- Revenue, trailing twelve months
- $5.5M
- Free cash flow, trailing twelve months
- −$133M
- Net income, trailing twelve months
- −$150M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
On our screens:Most shorted stocks